Company profile: BioMark Diagnostics
1.1 - Company Overview
Company description
- Provider of oncology-focused metabolomics-based cancer detection solutions, including a liquid biopsy metabolic panel for early lung cancer diagnosis using urine and plasma, a non-invasive SSAT1 assay leveraging an FDA-approved drug to detect elevated enzyme levels in cancers, a metabolomics-driven detection platform, lung cancer early detection studies, and cancer education videos.
Products and services
- Cancer Detection Platform: A metabolomics-based platform that identifies over-expressed enzymes in cancer cells for early cancer detection, engineered to characterize enzyme overexpression patterns
- Liquid Biopsy Metabolic Panel: A high-powered, metabolomics-driven liquid biopsy assay for early lung cancer diagnosis, analyzing urine and plasma samples to quantify metabolic signatures indicative of tumor presence
- SSAT1 Assay: A non-invasive assay that detects elevated levels of the enzyme SSAT1 in various cancers using an FDA-approved drug, enabling early identification of enzymatic dysregulation.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioMark Diagnostics
Immunitas Therapeutics
HQ: United States
Website
- Description: Provider of single-cell genomics and machine learning-based drug discovery to modulate oncology targets; antibody discovery and engineering; biomarker development; and IMT-009, an immuno-oncology a-CD161 mAb in clinical evaluation for solid tumors and hematological malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunitas Therapeutics company profile →
SmartHealth Dx
HQ: United States
Website
- Description: Provider of precision diagnostics addressing unmet clinical needs in vascular, metabolic, and oncological diseases, including SmartVascular Dx (blood test for vascular inflammation and stroke risk), SmartLung Dx (noninvasive test to identify benign lung nodules), SmartKidney Dx (metastasis risk in kidney disease), SmartScience Dx (~195,000-sample serum repository for biomarker discovery), and SmartPath Dx (real-time pathology imaging).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SmartHealth Dx company profile →
Adaptimmune
HQ: United Kingdom
Website
- Description: Provider of T-cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases, including afami-cel, a single-dose T-cell therapy targeting cancer, and lete-cel, a single-dose T-cell therapy in development for treating solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptimmune company profile →
Valitor Bio
HQ: United States
Website
- Description: Provider of novel methods to modify therapeutic proteins for control over pharmacological properties, including VLTR-559, a long-acting treatment for wet age-related macular degeneration designed to extend a single dose to six months or more; VLTR-557, a long-acting anti-VEGF biologic with potential six-month efficacy from one intravitreal injection; and Multivalent Polymer (MVP) Technology to enhance potency, durability, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valitor Bio company profile →
Flare Therapeutics
HQ: United States
Website
- Description: Provider of precision therapies by targeting transcription factors, including FX-909, a first-in-class small molecule PPARG inhibitor in Phase 1 for advanced solid malignancies such as advanced urothelial carcinoma. Offers a discovery engine and a pipeline of TF-targeted drug programs, with switch site identification, ligandability, and pharmacology capabilities, initially focused on precision oncology and expanding to metabolic, neurology, immunology/inflammation, and rare genetic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flare Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioMark Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioMark Diagnostics
2.2 - Growth funds investing in similar companies to BioMark Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioMark Diagnostics
4.2 - Public trading comparable groups for BioMark Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →